glutathione skin lightening dosage for lightening: a regnant myth or evidence-based verity? Unlock Glutathione IV Dose for

Moreau P, Garfall AL, van de Donk N, et al

Inhibiting adhesion events by Panax notoginseng saponins and ginsenoside Rb1 protecting arteries via activation of Nrf2 and suppression of p38 - VCAM-1 signal pathway

RGN-352 was shown to be safe and well-tolerated with no serious drug-related adverse events reported (PMID: 20536472) Phase 2 AMI trial (incomplete): RegeneRx designed a Phase 2 proof-of-concept trial (NCT01311518) to evaluate RGN-352 in approximately 75 patients with acute ST-segment elevation myocardial infarction (heart attack)

If a provider refuses or says the vial isnt available, that is a reason to leave